

Journal Pre-proof

Ocular surface reconstruction of Steven Johnson syndrome / toxic epidermal necrolysis affected eye - A case report

Tzu-Yun Tsai, Hou-Tai Chang, Shao-Wei Weng, Chan-Ching Chu, Yi-Chun Wang, Zhanqi Zhao, Elsa Lin-Chin Mai

PII: S2405-8440(22)03878-6

DOI: <https://doi.org/10.1016/j.heliyon.2022.e12590>

Reference: HLY 12590

To appear in: *HELIYON*

Received Date: 15 June 2022


Revised Date: 11 November 2022

Accepted Date: 15 December 2022

Please cite this article as: T.-Y. Tsai, H.-T. Chang, S.-W. Weng, C.-C. Chu, Y.-C. Wang, Z. Zhao, E.L.-C. Mai, Ocular surface reconstruction of Steven Johnson syndrome / toxic epidermal necrolysis affected eye - A case report, *HELIYON*, <https://doi.org/10.1016/j.heliyon.2022.e12590>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 The Author(s). Published by Elsevier Ltd.



**Ocular surface reconstruction of Steven Johnson syndrome / toxic epidermal necrolysis affected eye -
a case report**

Tzu-Yun Tsai, M.D.^{1,2#}, Hou-Tai Chang, Ph.D.^{3,5,6#}, Shao-Wei Weng, M. PH¹, Chan-Ching Chu, B. RT⁴, Yi-Chun Wang, B. RT⁴, Zhanqi Zhao, Ph.D.^{7,8}, Elsa Lin-Chin Mai, M.D, M.PH^{1,9*}

¹Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City, Taiwan

²Department of Ophthalmology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.

³Center of Hyperbaric Oxygen, Far Eastern Memorial Hospital, New Taipei City, Taiwan

⁴Department of Chest Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan

⁵Department of Critical Care Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan

⁶Department of Industrial Engineering and Management, Yuan Ze University, Taoyuan, Taiwan

⁷ Department of Biomedical Engineering, Fourth Military Medical University, Xi'an, China

⁸ Institute of Technical Medicine, Furtwangen University, Villingen-Schwenningen, Germany

⁹ Department of Optometry, Yuanpei University of Medical Technology, Hsinchu, Taiwan

TYT and HTC contributed equally to this study.

*Corresponding author: Elsa Lin-Chin Mai, MD, MPH

Far Eastern Memorial Hospital, Taipei, Taiwan, No. 21, Sec. 2, Nanya S. Rd., Banciao Dist., New Taipei City 220, Taiwan (R.O.C.)

Telephone: +886-2-89667000-1376; E-mail: elsamark@yahoo.com

Abbreviations:

AMT, amniotic membrane transplantation; CLAL, conjunctival limbal allograft; CLAU, conjunctival limbal autograft; CLET, cultivation of autologous limbal epithelial transplantation; HBOT, hyperbaric oxygen therapy; KLAL, keratolimbal allograft; LSC, limbal stem cell; LSCD, limbal stem cell deficiency; LSCT, limbal stem cell transplantation; SLET, Simple limbal epithelial transplantation; SJS, Steven Johnson syndrome; TEN, toxic epidermal necrolysis; VA, visual acuity

Abstract

Introduction: Toxic epidermal necrolysis (TEN), also known as Steven Johnson syndrome (SJS), is a devastating disease. Patients develop blindness and symblepharon despite multiple reconstructive surgeries. We report a case of SJS/TEN with ocular involvement where treatment with hyperbaric oxygen therapy (HBOT) resulted in a significant improvement in the visual acuity after surgery.

Case Presentation: A woman with SJS/TEN with severe ocular involvement had limbal stem cell deficiency and symblepharon of the superior and inferior fornix. Pannus grew over her cornea, reducing the vision to finger counting. The symblepharon produced shortening of the fornix, causing entropion. The in-turned eyelid caused her eyelashes to rub against the cornea, causing great pain to the patient. Limbal stem cell deficiency led to the loss of normal corneal morphology and invasion of the pannus onto the central visual axis, resulting in poor vision. She experienced ocular inflammation for 3 months before admission. Ophthalmic examination showed bilateral corneal opacity with conjunctivalization, and inferior and superior fornix shortening. Symblepharon-lysis with amniotic membrane transplantation was attempted but the outcome was poor, with recurrence of superior scarring and symblepharon. She finally underwent major reconstructive surgery with limbal stem cell transplantation with her sister as the donor, autologous minor salivary gland transplantation, and oral buccal mucosa flap transplant. HBOT was given daily post-surgery for supporting the grafts and suppressing inflammation. After 17 HBOT sessions and 3 months of autoserum drops, her left eye vision increased from the initial finger counting to 0.4 due to the successful growth of the corneal epithelium from the donor corneal limbal cell line. When a scleral contact lens which vaulted over the corneal limbal area was fitted, her vision improved to 0.8 due to redressal of high order aberration and astigmatism from the cornea scar.

Conclusion: After major reconstruction of the ocular surface with multiple cell type transplants, including limbal stem cells, minor salivary gland acinar cells, and oral mucosa cells, HBOT proved useful in supporting the graft uptake and oxygenation of the donor tissues, enabling fast recovery of the grafts and cell functioning, with eventual return of the working vision of the patient.

Keywords: Stevens-Johnson syndrome, Toxic epidermal necrolysis, Limbal stem cell deficiency, hyperbaric oxygen therapy, case report

Introduction

Steven Johnson syndrome (SJS)/ toxic epidermal necrolysis (TEN) is a potentially fatal mucocutaneous adverse drug reaction, characterized by extensive epithelial cell necrosis and shedding, and a high mortality rate [1]. Our patient had SJS/TEN with severe eye involvement, and was treated with an oral mucosal graft, minor salivary gland transplant, and limbal stem cell transplant. Postoperatively, hyperbaric oxygen therapy (HBOT) was started to support wound healing. HBOT is given by placing the whole body in a hyperbaric chamber, applying pressure greater than 1.4 absolute atmospheric pressure, and inhaling 100% pure oxygen directly or indirectly. Studies have confirmed the usefulness of HBOT in diabetes-related wounds, as it promotes wound healing and enhances the effect of antibiotics [2]. In ophthalmology, HBOT has demonstrated a beneficial effect in ocular diseases such as central retinal arterial/venous occlusion, branch retinal venous occlusion, and recurrent pterygium by mitigating hypoxia, facilitating wound healing, and reducing inflammation [3, 4]. In this case report, we have described the impact of SJS/TEN on the eye, along with the surgical management and HBOT. We have also reviewed literature to discuss the mechanism of HBOT in corneal wound healing and its benefits in complicated grafts.

Case presentation

Patient history

A 30-year-old woman was referred for SJS/TEN with ocular involvement caused by an adverse reaction to lamotrigine for her seizure disorder. She initially had a progressive red rash and blisters on her mouth, nose, trunk, and extremities plus severe ocular complications. She was admitted to the intensive care unit due to profound skin necrosis and an ophthalmology consultation was immediately sought for sight-threatening complications of both eyes. She received lubricants, anti-inflammatory eyedrops, and an amniotic membrane device (Prokera®); however, her condition deteriorated. Due to the persistent corneal epithelial defect, corneal haze, and symblepharon, she was referred to our tertiary hospital after one month.

Clinical examination

The initial slit lamp examination showed a total epithelial defect with severely engorged vessels, inflamed eye, corneal neovasculation pannus, and symblepharon with loss of the fornix in both eyes (Figure 1A).

The visual acuity (VA) in both eyes was decreased to counting finger (less than 0.05). She underwent debridement surgery with symblepharon-lysis and amniotic membrane transplantation (AMT) twice in her left eye. Although the epithelial defect subsequently improved gradually, her condition fluctuated with poor epithelial growth, whorl-like epitheliopathy with fluorescein pooling, abnormal epithelial opaque deposition, recurrent neovascularization, and prominent pannus ingrowth onto the central cornea (Figure 1A-D); the poor corneal condition was attributed to limbal stem cell (LSC) deficiency. Despite two additional AMT patch grafts, her vision soon deteriorated to only light perception in the right eye and hand-motion in the left eye. Total limbal stem cell deficiency (LSCD) was diagnosed. Her Ocular Surface Grading Score (OSGS) was 14 and the results of Schirmer's test without anesthesia was 0 mm in 5 minutes before surgery. After considering the vision-threatening consequence, she agreed to undergo major ocular reconstruction surgeries to salvage her eyesight.

Therapeutic Intervention

The surgeries included allogeneic conjunctival-limbal stem cell transplantation, autologous buccal and labial mucosal flap with minor salivary gland transplant, and AMT patch graft in the left eye. The patient's sister was identified as an appropriate donor after HLA-typing evaluation of her close family members (Table1). The patient's HLA typing was performed before surgery, her HLA typing were as listed. Our laboratory has specifically looked for HLA-B*13:01, HLA-B*15:02, HLA-B*57:01, HLA-B*58:01, and HLA-B*27 alleles, but these show up negative. According to her Serology typing of HLA-B locus which is 38, 56, she should also be negative for HLA-B 46:01. The patient underwent symblepharon-lysis with all kerato-conjunctival pannus removal. Conjunctiva-limbal allograft was obtained from the upper and lower limbus with a size of 5×7 mm from her sister, and transferred to the patient at the approximate location. Simple limbal epithelial transplantation (SLET) was also performed by gluing extra limbal tissues onto the central denuded cornea with fibrin glue (Artiss®). Simultaneously, minor salivary gland transplantation labial and buccal area, mucous membrane graft from the patient's oral buccal mucosa, and AMT patch graft over the SLET and conjunctiva limbal graft were performed (Figure 2).

Due to the complicated situation and multiple at-risk grafts, we administered HBOT as an adjunctive therapy to promote graft survival, cornea limbal epithelium healing, and minor salivary gland and mucosa

graft uptake. Pre-procedure, it was decided that HBOT should comprise a daily session with bottom depth of 10 meters (2.0 ATA) and bottom time of 75 minutes with a 5-minute air-break in between to avoid seizure relapse. She was placed in a hyperbaric chamber with the applied pressure greater than 1.4 absolute atmospheric pressure, and 100% pure oxygen was inhaled directly. The patient had no HBOT-associated side effects and endured the pressure transection with ease. Meanwhile, supportive ophthalmologic treatments such as frequent lubricant, topical steroid, and auto-serum were continued. After 17 sessions of HBOT, complete re-epithelialization of the eye was noted at the 1-month follow-up. The ocular surface was wet with mucoidal secretion from her upper fornix, showing minor salivary gland activation. The mucosa flap was noticeably viable with vasculature and attachment to the tarsal plate, and no visible synechia of the conjunctiva to the cornea. At the 3-month visit, uncorrected VA in her left eye had improved to 0.4, and with scleral lens correction, VA of (0.8) could be obtained. Slit-lamp examination revealed smooth corneal epithelium and a faint corneal scar at the site of the original corneal pannus along with para-central haze induced by an epithelium defect from trichiasis (Figure 1E, F). Four month after operation, her Ocular Surface Grading Score (OSGS) improvement to 3 (Figure 3A-D) and the results of Schirmer's test without anesthesia was 6 mm in 5 minutes.

Discussion

The transparency of the corneal epithelial surface is maintained by LSCs [5], which are located in the basal layer of the limbal area [6]. This area has a protective environment called the niche in the border between the sclera/conjunctiva and cornea [3, 7]. LSCD is a condition where insufficient number of functional LSCs reach the cornea surface, and can be caused by many pathologies, such as genetic defects, systemic immune-mediated diseases, or a secondary injury to the LSC niche and its microenvironment [5]. LSCD impairs the ability of the corneal epithelium to repopulate itself, leaving the denuded cornea to be overrun by the invading conjunctiva and fibrotic tissues. Therefore, LSCD with SJS/TEN usually has a poor visual outcome [8]. Patients with LSCD often experience redness, irritation, photophobia, and decreased vision from corneal opacity and irregular astigmatism. Initially, the epithelium becomes wavy, irregular, and hazy, progressing to persistent corneal epithelial defects, stromal scarring, ulceration, and even perforation.

Conservative treatment, such as the intensive use of nonpreserved lubrication and topical corticosteroids, only provides temporary remission, and the condition deteriorates over time if LSCs are not replenished. Surgical options include the removal of corneal conjunctivalization, with or without concurrent AMT and different types of reconstruction with LSCs to restore the normal corneal structure and function [9]. Ocular surface reconstruction for LSCD can involve limbal stem cell transplantation (LSCT) with transplantation of the normal conjunctiva plus limbus graft in conjunctival limbal autograft (CLAU) from the contralateral healthy eye, or allograft from a cadaver/living donor (keratolimbal allograft (KLAL)/conjunctival limbal allograft (CLAL) [7] when there is no healthy contralateral eye available. Other options are cultivation of autologous limbal epithelial transplantation (CLET) if sufficient laboratory facility is available [10], and simple limbal epithelial transplantation (SLET), a modified form of CLAU. This method reportedly has a better success rate in the treatment of unilateral LSCD induced by chemical burns, and is more tissue saving for the donor eye [11]. A systemic review by Ganger et al. found that although the anatomical success rates were similar among SLET, CLET, CLAL, and KLAL (63.65%~79.8%), the functional outcome in terms of the gain in the post-operative VA was better with KLAL and SLET than CLET [12]. Hence, we selected a combination of CLAL and SLET. To ensure successful limbal epithelium regrowth, a wet environment suitable for the survival of LSCs and transient amplifying cornea epithelium cells must be created; therefore, aqueous and mucin must be replenished. Accordingly, we transplanted the minor salivary gland, mucosa flap graft, and amniotic membrane patch graft along with LSCT. Postoperatively, the wounds may experience hypoxia due to the breakdown of the ocular surface circulation. As the cornea is avascular, it normally acquires oxygen directly from the atmosphere. In our patient, after amniotic membrane patch graft and LSC coverage, a reduction in the atmospheric oxygen supply was likely to impair the corneal physiology and function. According to previous studies, hypoxia impairs the integrity of the corneal cell junctions and causes neovascularization [13]. Zieske et al. also found that the cornea becomes vascularized with pannus formation due to hypoxia during disease or trauma [14]. However, evidence has been controversial regarding LSC survival, with one cell-based study showing that human corneal epithelium stem cells cultured in hypoxic conditions may exhibit a quiescent stem cell phenotype and survive longer [15]. According to Ma et al. collected all 26 diagnosed SJS/TEN patients with severe

ocular complications (SOC) in Taiwan, the HLA-A*02:07 carrier frequency was significant ($p=0.049$), as was the genotype frequency ($p=0.007$). In SJS/TEN patients with SOC, HLA-A*02:07 carrier frequency was higher ($p=0.016$), as was allele frequency ($p=0.001$). The HLA-B*46:01 allele frequency was significantly higher in SJS/TEN patients with SOC ($p=0.008$). Therefore, the HLA-A*02:07 and HLA-B*46:01 alleles are significantly correlated with the SOC of the Han SJS/TEN patient, But in our case, her HLA typing was HLA-A 02, 24; HLA-B 38,56; HLA-C 01, 07, therefore she was negative for HLA-B*13:01, HLA-B*15:02, HLA-B*57:01, HLA-B*58:01, HLA-B* 27 and HLA-B*46:01 alleles. Since her HLA-A typing were 02,24, she can probably be a HLA-A* 0207[16]. The hypoxia related vicious cycle may impede and damage the self-healing process of the ocular surface due to matrix protein deposition and focal adhesion protein loss, leading to re-epithelialization failure and decreased surgical success rate [17, 18]. Apart from the controversy regarding LSCs, other at risk graft transplantations are well documented to benefit from HBOT induced hyperoxygenation [19]. We used HBOT to increase the survival rate of the multiple grafts in the SJS/ TEN compromised environment based on the following assumptions. First, HBOT improves oxygenation of the graft directly by immersing the graft in 100% oxygen, whereas the normal environment is only 20% oxygenated. This allows survival until the graft develops its own blood supply from the scleral/ conjunctiva bed [20]. Second, oxygen upregulates a number of cytokines and growth factors, such as transforming growth factor-1 and platelet-derived growth factor, which facilitate corneal re-epithelialization [4]. Third, HBOT stimulates angiogenesis and reduces wound edema by an osmotic effect, thus promoting oxygen diffusion and wound healing [4]. Fourth, HBOT is known to have an anti-inflammatory effect [21], which may avoid the recurrence of symblepharon or fornix shortage. An animal study on chemical burns in the cornea showed that oxygen therapy improved prelimbic conjunctiva ischemia and promoted corneal epithelial healing [22]. Therefore, in corneal hypoxia and contact lens wearing incidents, HIF-1 α , IL-8, IL-6 and angiopoietin are restricted. The expression of 12-HETE, 12-HETrE and VEGF increased during contact lens wear. As in other tissues, the corneal hypoxic response requires an imbalance of pro- and anti-angiogenic mediators. IPAS domain proteins, endostatin, angiostatin, PEDF, and erythropoietin are candidates for important mediators of anti-angiogenesis. Therefore, when hyperbaric oxygen therapy is applied with 2.0ATA for 75 minutes,

sufficient oxygen obtained by the corneal cells can obtain partial pressure of oxygen are 1500 mmHg, which is about 15 times the original partial pressure of oxygen, so the corneal vascular hyperplasia will be decreased [23]. We administered HBOT to our patient. Based on past experience and literature, Hyperbaric oxygen therapy is a very safe treatment method, but there may still be some side effects and complications, such as following symptoms: ear barotrauma, dizziness, dyspnea, palpitations, and cold sweats. The incidence of the above-mentioned possible complications is low and most of them are reversible. The more serious complications include: Oxygen toxicity, seizures, pneumothorax, cardiac arrhythmia, but rarely happen. we speculate that the wound-healing mechanism of HBOT worked as follows: A minimum of 20 mmHg partial pressure of oxygen is required for wound healing, including fibroblast proliferation and collagen production; under hyperbaric oxygen conditions, the partial pressure of oxygen can be brought up to 280-350 mmHg, which enables proper cellular function and promotes wound healing [24]. Considering the successful recovery of our patient, HBOT seems to be effective and should be advocated as an adjuvant therapy for ocular surface reconstruction in SJS/ TEN.

Conclusion

SJS/TEN can have serious systemic and ocular sequelae, including vision-threatening ocular complications and high mortality. Even with ocular reconstruction surgery, the success rates are often low. We highlighted an innovative method of combining simultaneous ocular surface reconstruction surgeries, including oral mucosa flap graft, minor salivary gland transplant, allogeneic conjunctival LSCT, and simple limbal epithelial transplantation in one setting, followed by postoperative HBOT as adjuvant treatment. This resulted in promising recovery of the vision and ocular surface.

However, more clinical studies are needed to verify the benefits of HBOT for ocular surface reconstruction surgeries.

Acknowledgements

We thank Mei-Yun Chang and Tsai- Fen Chen (Center of Hyperbaric Oxygen, Far Eastern Memorial Hospital).

Funding

This study was financially supported by the project Far Eastern Memorial Hospital (FEMH-2020-C-008).

Conflict of Interest

The authors report no conflict of interest.

Patient Consent

The patient provided a written informed consent for inclusion of her clinical and imaging details in the manuscript for the purpose of publication.

Data Availability Statement

Data is available upon reasonable request to the corresponding author.

Table1. The biomarker human leucocyte antigen (HLA) typing of the patient and her sister (donor)

Figure legends

Figure 1. The profound pannus ingrowth onto the cornea after limbal stem cell deficiency (LSCD) [A] and fluorescence revealed bizarre ocular surface in her left eye [B]. Symblepharon causes superior fornix shortening [C] and vision occlusion by pannus formation [D]. After surgical procedure of allogeneic LSCT with living-related conjunctival limbal allograft (lr-CLAL) & SLET, combined with 17 times of HBOT. Postoperative 4-month image showing a stable well-epithelialized ocular surface with no neovascularization, a faint residual deep stromal scarring as seen in the left eye [E], fluorescence staining of the same eye shows no cornea epithelium defect and stable tear film [F].

Figure2. Illustration of surgical procedure

A. Pannus removal from disease eye of bulbar conjunctiva and Palpebral conjunctiva.

B. Buccal mucosal flap and minor salivary gland transplantation.

B1. Oral buccal mucosa taken from patient's right cheek, sliced into 2 pieces, then transplanted to the patient's upper and inferior palpebral conjunctiva

B2. Minor salivary gland taken from patient's left labial area transplanted to diseased eye's superior conjunctiva and superior fornix.

C. Lr-CLAL (living relative conjunctiva limbal allograft) + SLET (Simple Limbal Epithelial Transplantation). The limbal stem cell within the conjunctiva limbal graft is taken from her sister's donor eye, suture to the patients' superior and inferior limbus area, extra limbus tissue was sliced into small pieces, and then transplanted to patient's central denuded cornea.

D. Amniotic membrane, taken from uterus, was grafted over the patient's cornea, bulbar conjunctiva, upper and lower fornix, palpebral conjunctiva.

Figure 3. Eye count distribution by total Ocular Surface Grading Score (OSGS) and images of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) patients. C, conjunctivalization; N, neovascularization; O, opacification; K, keratinization; S, symblepharon; U, upper conjunctival sac shortening; L, lower conjunctival sac shortening; T, total OSGS. (A-B) Pre-operation surgery OSGS status: pre-operation (C3,N3,O2,K0,S2,U2,L2:T14), (C-D) Post operation 4 months OSGS status: Post-operation after 4 months (C2,N0,O1,K0,S0,U0,L0:T3)

REFERENCES

1. Harr, T. and L.E. French, *Toxic epidermal necrolysis and Stevens-Johnson syndrome*. Harr and French Orphanet Journal of Rare Diseases, 2010. **5**(39).
2. Niinikoski, J.H., *Clinical hyperbaric oxygen therapy, wound perfusion, and transcutaneous oximetry*. World J Surg, 2004. **28**(3): p. 307-11.
3. Tsai, R.J. and S.C. Tseng, *Human Allograft Limbal Transplantation for corneal surface reconstruction.pdf*>. Cornea, 1994. **13**(5): p. 389-400.
4. Sharifipour, F., et al., *Oxygen therapy for acute ocular chemical or thermal burns: a pilot study*. Am J Ophthalmol, 2011. **151**(5): p. 823-8.
5. Deng, S.X., et al., *Global Consensus on the Management of Limbal Stem Cell Deficiency*. Cornea, 2020 **39**: p. 1291-1302.
6. Cotsarelis, G., et al., *Existence of Slow-Cycling Limbal Epithelial Basal Cells That Can Be Preferentially Stimulated to Proliferate Implications on Epithelial Stem Cells*. Cell, 1989. **57**(2): p. 201-209.
7. SCG, T., et al., *Limbal stem cells transplantation*. Ophthalmol Clin North Am . 1990. **3**: p. 595–610.
8. Choi, S.H., M.K. Kim, and J.Y. Oh, *Corneal Limbal Stem Cell Deficiency in Children with Stevens-Johnson Syndrome*. Am J Ophthalmol, 2019. **199**: p. 1-8.

9. Kim, K.H. and S.I. Mian, *Diagnosis of corneal limbal stem cell deficiency*. *Curr Opin Ophthalmol*, 2017. **28**(4): p. 355-362.
10. Pellegrini, G., et al., *Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium*. *The Lancet*, 1997. **349**(9057): p. 990-993.
11. Sangwan, V.S., et al., *Simple limbal epithelial transplantation (SLET): a novel surgical technique for the treatment of unilateral limbal stem cell deficiency*. *Br J Ophthalmol*, 2012. **96**(7): p. 931-4.
12. Ganger, A., et al., *Outcomes of surgical interventions for the treatment of limbal stem cell deficiency*. *Indian J Med Res*, 2021. **154**(1): p. 51-61.
13. Kehasse, A., et al., *Epithelial wounds induce differential phosphorylation changes in response to purinergic and EGF receptor activation*. *Am J Pathol*, 2013. **183**(6): p. 1841-1852.
14. JD, Z., et al., *Activation of epidermal growth factor receptor during corneal epithelial migration*. *Invest Ophthalmol Vis Sci*, 2000. **41**: p. 1346-1355.
15. Hallam, D., et al., *The effect of hypoxia on the growth of limbal stem cells*. *Investigative Ophthalmology & Visual Science* 2013. **54**: p. 982.
16. David H K Ma, et al., *Human leucocyte antigen association of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications in Han Chinese*. *British Journal of Ophthalmology* 2022 May;106(5):610-615.
17. Onochie, O.E., et al., *The Role of Hypoxia in Corneal Extracellular Matrix Deposition and Cell Motility*. *Anat Rec (Hoboken)*, 2020. **303**(6): p. 1703-1716.
18. Lee, A., et al., *Hypoxia modulates the development of a corneal stromal matrix model*. *Exp Eye Res*, 2018. **170**: p. 127-137.
19. Oguz, H. and G. Sobaci, *The use of hyperbaric oxygen therapy in ophthalmology*. *Surv Ophthalmol*, 2008. **53**(2): p. 112-20.
20. N., N., et al., *Use of Adjuvant Hyperbaric Oxygen Therapy to Support Limbal Conjunctival Graft in the Management of Recurrent Pterygium*. *Cornea*, 2011. **30**: p. 7-10.
21. McCrary, B.F., *Hyperbaric oxygen (HBO2) treatment for a failing facial flap*. *Postgrad Med J*, 2007. **83**(975): p. e1.

22. L.W., H., et al., *Controlled trial of hyperbaric oxygen treatment for alkali corneal burn in the rabbit*. Clin Experiment Ophthalmol 2004. **32**: p. 67-70.
23. Safvati, A., et al., *Mediators of neovascularization and the hypoxic cornea*. Curr Eye Res, 2009. **34**(6): p. 501-14.
24. JR, H. and S. MS, *Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis*. J Foot Ankle Surg, 2002. **41**: p. 291-299.





Journal Pre-proof




Table 1. Biomarker human leucocyte antigen (HLA)typing of the patient and her sister

Pharmacogenetics(the patient)	the result	Pharmacogenetics(the donor)	the result
HLA-B*15:02	Negative	HLA-B*15:02	Negative
HLA-B*58:01	Negative	HLA-B*58:01	Negative
HLA-B*13:01	Negative	HLA-B*13:01	Negative
HLA-B*57:01	Negative	HLA-B*57:01	Negative
HLA-A*31:01	Negative	HLA-A*31:01	Negative
A Locus Serology	2, 24	A Locus Serology	2, 24
A Locus Molecular	02, 24	A Locus Molecular	02, 24
B Locus Serology	38, 56	B Locus Serology	38, 60
B Locus Molecular	38, 56	Bw Locus Serology	4, 6
C Locus Serology	1, 7	C Locus Serology	7
C Locus Molecular	01, 07	C Locus Molecular	7
Bw Locus Serology	4, 6	B Locus Molecular	38, 40
DR Locus Serology	15, 16		
DQ Locus Serology	5, 6	HLA-DR,DQ typing	
DRw Serology	51, -	DR Locus Serology	14, 16
DRB1 Locus Molecular	15, 16	DQ Locus Serology	5
DRB3 Locus	Negative	DRw Serology	52, 51
DRB4 Locus	Negative	DRB1 Locus Molecular	14, 16

DRB5 Locus	Positive	DRB3 Locus	Positive
DQB1 Locus Molecular	05, 06	DRB4 Locus	Negative
HLA-ABC	*	DRB5 Locus	Positive
HLA-DR,DQ typing	*	DQB1 Locus Molecular	5

Journal Pre-proof






Journal

(A)



Patient's eye



B1




B2



salivary gland transplantation

(C)




Limbal stem cell graft

Donor's eye




Sliced limbal graft



Patient's eye

(D)



Uterus

(B)

